Drugs / Recombinant COVID-19 Vaccine (Sf9 Cell)
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05463354 | Jul → Aug 2022 | COVID-19 | WestVac Biopharma Co., Ltd. | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT06381843 | Aug 2022 → Mar 2023 | COVID-19 | WestVac Biopharma Co., Ltd. | Completed | No outcome recorded |
| — | NCT05465785 | Jul 2022 → Mar 2023 | COVID-19 | WestVac Biopharma Co., Ltd. | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05770180 Comparator | Mar → Jul 2023 | COVID-19 | WestVac Biopharma Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant COVID-19 Vaccine (Sf9 Cell) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06381843 ↗ |
| Modality | Vaccine | “Recombinant COVID-19 Vaccine” NCT05463354 ↗ |
| Route | Intramuscular | “Intramuscular Injection” NCT05463354 ↗ |